Takeda
AmericasTakeda received Japanese regulatory approval (MHLW) for ORZEYFUL (oveporexton), a first-in-class oral orexin receptor 2 agonist for narcolepsy type 1. This is the first and only medicine in Japan indicated to treat the underlying cause rather than individual symptoms. Company is proceeding with launch preparations.
curated · 2026-08-24 · context →
Takeda is pursuing inclusion of its dengue vaccine in India's national immunisation program (likely the Universal Immunisation Programme).
curated · 2026-08-05 · context →
Takeda's dengue vaccine (TAK-003) received India's Drug Controller General of India (DCGI) marketing authorization approval, becoming India's first-ever approved dengue vaccine. The vaccine is approved for ages 4-60 without pre-vaccination testing, regardless of previous dengue exposure.
curated · 2026-07-22 · context →
Takeda announced landmark collaboration with Indonesian Government and received fractionation license from Ministry of Health, marking major expansion into Indonesia's biopharmaceutical manufacturing and plasma-derived medicinal products market
curated · 2026-07-12 · context →
Takeda appointed first female CEO who is prioritizing AI integration across biopharma business operations
curated · 2026-06-26 · context →
Julie Kim officially appointed as Takeda's Representative Director, President and Chief Executive Officer, completing an 18-month CEO transition
curated · 2026-06-24 · context →
Takeda announced restructuring plan with 4,500 worker layoffs
curated · 2026-05-15 · context →
